Patents by Inventor Suneel Gupta

Suneel Gupta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
    Publication number: 20250134818
    Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.
    Type: Application
    Filed: December 30, 2024
    Publication date: May 1, 2025
    Applicant: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
    Patent number: 12274793
    Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.
    Type: Grant
    Filed: October 10, 2024
    Date of Patent: April 15, 2025
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Levodopa dosing regimen
    Patent number: 12263149
    Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Grant
    Filed: August 28, 2024
    Date of Patent: April 1, 2025
    Assignee: Amneal Pharmaceuticals, LLC
    Inventors: Richard D′Souza, Hester Visser, Suneel Gupta
  • Levodopa dosing regimen
    Patent number: 12263148
    Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Grant
    Filed: August 13, 2024
    Date of Patent: April 1, 2025
    Assignee: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
    Publication number: 20250099389
    Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains a decarboxylase inhibitor wherein the one or more controlled release components are substantially free of the decarboxylase inhibitor.
    Type: Application
    Filed: December 10, 2024
    Publication date: March 27, 2025
    Applicant: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
    Publication number: 20250032421
    Abstract: The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components.
    Type: Application
    Filed: October 10, 2024
    Publication date: January 30, 2025
    Applicant: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Dong, Suneel Gupta
  • Levodopa dosing regimen
    Patent number: 12201596
    Abstract: The invention is a method for treating patients with post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Grant
    Filed: September 3, 2024
    Date of Patent: January 21, 2025
    Assignee: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • Levodopa dosing regimen
    Patent number: 12194150
    Abstract: The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: January 14, 2025
    Assignee: Amneal Pharmaceuticals LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • LEVODOPA DOSING REGIMEN
    Publication number: 20250000831
    Abstract: The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Application
    Filed: September 3, 2024
    Publication date: January 2, 2025
    Applicant: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
    Patent number: 12178919
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
    Type: Grant
    Filed: August 1, 2024
    Date of Patent: December 31, 2024
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
    Patent number: 12178918
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
    Type: Grant
    Filed: June 26, 2024
    Date of Patent: December 31, 2024
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • LEVODOPA DOSING REGIMEN
    Publication number: 20240423940
    Abstract: The invention is a method for treating patients with post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Application
    Filed: September 3, 2024
    Publication date: December 26, 2024
    Applicant: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • LEVODOPA DOSING REGIMEN
    Publication number: 20240423939
    Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “Off” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Application
    Filed: August 28, 2024
    Publication date: December 26, 2024
    Applicant: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATION OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
    Publication number: 20240398713
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
    Type: Application
    Filed: August 1, 2024
    Publication date: December 5, 2024
    Applicant: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • LEVODOPA DOSING REGIMEN
    Publication number: 20240398744
    Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Application
    Filed: August 13, 2024
    Publication date: December 5, 2024
    Applicant: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • LEVODOPA DOSING REGIMEN
    Publication number: 20240398743
    Abstract: The invention is a method for treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Application
    Filed: August 13, 2024
    Publication date: December 5, 2024
    Applicant: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof
    Patent number: 12128141
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
    Type: Grant
    Filed: July 31, 2024
    Date of Patent: October 29, 2024
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF
    Publication number: 20240350417
    Abstract: The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a muco-adhesive coating and the muco-adhesive coating is externally coated with an enteric coating; and (b) an immediate release component comprising levodopa. The invention further provides a method for making and using the oral solid formulation.
    Type: Application
    Filed: June 26, 2024
    Publication date: October 24, 2024
    Applicant: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Levodopa dosing regimen
    Patent number: 12109185
    Abstract: The invention provides oral dosing regimens of controlled release levodopa compositions for use in treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and the dosing regimens provide an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Grant
    Filed: April 12, 2024
    Date of Patent: October 8, 2024
    Assignee: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta
  • LEVODOPA DOSAGE FORM
    Publication number: 20240315999
    Abstract: The invention is a multiparticulate controlled release dosage form comprising 350 mg of levodopa for use in treating patients with Parkinson's disease, primary parkinsonism/idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
    Type: Application
    Filed: June 3, 2024
    Publication date: September 26, 2024
    Applicant: Amneal Pharmaceuticals, LLC
    Inventors: Richard D'Souza, Hester Visser, Suneel Gupta